Most Recent
Dairy giant Fonterra has lost its bid to stop Vitasoy from registering its slogan ‘Growing Milk Since 1940’ as a trade mark, after unsuccessfully arguing that consumers would be misled by the lack of animal milk in Vitasoy’s soy and almond milk products.
US prenatal genetic test maker Ariosa Diagnostics has won its bid to appeal a ruling that its Harmony test infringed a patent owned by rival Sequenom.
A mortgage broker has successfully opposed REA Group's application to trade mark "realestate.com.au Home Loans", with a delegate finding the mark is not adapted to distinguish REA's online services.
US tobacco giant Philip Morris has failed in its challenge before IP Australia to rival British American Tobacco's application for a trade mark to be used on its electronic cigarettes.
Beverage giant Monster Energy has appealed a ruling that allowed a company associated with leading tyre retailer Bob Jane T-Mart to register trade marks for its Monster brand alloy wheels.
A court has barred US drug company Merck Sharp & Dohme from denying that an agreement made with German pharmaceutical company Merck KGaA was governed by German law, settling a key question before a trade mark case between the two drug giants goes to trial.
A court has found Ariosa Diagnostics infringed a patent held by Sequenom for a noninvasive prenatal genetic test, and ruled one claim of the patent invalid for lack of fair basis.
A judge has allowed a company associated with leading tyre retailer Bob Jane T-Mart to register three trade marks for its brand of Monster alloy wheels, dismissing claims from US energy drink giant Monster Energy that allowing the registration would lead to confusion.
A developer of what's now being called the "Infamous Mod" for video game Grand Theft Auto, which gives players extra powers, is confident he can defend the copyright case brought against him by Take-Two Interactive and its subsidiary Rockstar Games.
A proposed Novartis patent for an oral form of its top-selling multiple sclerosis drug Gilenya is invalid for lack of inventive step, IP Australia has found, but gave the pharmaceutical giant a chance to amend.